吉非替尼与厄洛替尼二线治疗晚期肺腺癌的临床疗效及安全性  

Clinical effect and safety of gefitinib and erlotinib second line treatment of lung adenocarcinoma

作　　者：张雅军[1] 李红兵[1] 李现东[1] 刘笑春[1] 韩继昌[1] 

机构地区：[1]河南大学淮河医院呼吸科,河南开封475000

出　　处：《中国临床药理学杂志》2015年第11期899-901,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的探讨吉非替尼与厄洛替尼二线治疗晚期肺腺癌的临床疗效及安全性。方法接受吉非替尼或厄洛替尼的晚期肺腺癌患者86例,根据服药方案分为2组,吉非替尼组41例患者,口服吉非替尼250 mg,qd;厄洛替尼组45例患者,口服厄洛替尼150 mg,qd。2组患者均连续服至疾病进展或出现不可耐受性的药物不良反应。分析比较2组患者的客观疗效及安全性。结果 2组患者客观缓解率比较差异无统计学意义(24.3%vs 26.7%,P>0.05);吉非替尼组与厄洛替尼组的中位生存时间分别为13.5,13.2个月,2组患者生存时间经Logrank检验差别无统计学意义(P>0.05)。2组患者主要不良反应为皮疹和腹泻,2组不良反应发生率差异无统计学意义(P>0.05)。结论吉非替尼与厄洛替尼二线治疗晚期肺腺癌的临床疗效及安全性相当。Objective To evaluate the effects and safety of gefitinib ver-sus erlotinib second line treatment of lung adenocarcinoma.Methods Eight six pathology confirmed lung adenocarcinoma were included in this study.Patients in the gefitinib group were administered of gefitinib 250 mg orally per day until disease progression.Patients in the erlotinib group were given erlotinib150 mg orally per day until disease progression.The clinical activity such as objective response rate, median survival and toxicity were compared between the two groups.Results The objective response rate were 24.3%and 26.7%for the gefitinib group and erloti-nib group respectively with no statistical difference（P〉0.05）.The medi-an survival time were 13.5 months and 13.2 months in the gefitinib group and erlotinib group respectively with no statistical difference （ P〉0.05 ）.The main drug related toxicity were rash and diarrhea for the two groups with no significant difference （ P 〉0.05 ）.Conclusion Gefitinib and erlotinib were similar in the aspects of efficacy and drug related adverse events for the second line treatment of lung adenocarcinoma.

关 键 词：肺腺癌 吉非替尼 厄洛替尼 药物不良反应 

分 类 号：R734.2[医药卫生—肿瘤] R979.1[医药卫生—临床医学]